These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 38537514)

  • 1. Natural polyphenol: Their pathogenesis-targeting therapeutic potential in Alzheimer's disease.
    Niu C; Dong M; Niu Y
    Eur J Med Chem; 2024 Apr; 269():116359. PubMed ID: 38537514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
    Mazumder MK; Choudhury S
    Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural Compounds as Inhibitors of Aβ Peptide and Tau Aggregation.
    Monteiro KLC; de Aquino TM; da Silva-Júnior EF
    CNS Neurol Disord Drug Targets; 2024; 23(10):1234-1250. PubMed ID: 38018200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.
    Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C
    J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.
    Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK
    Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and Cellular Basis of Neurodegeneration in Alzheimer's Disease.
    Jeong S
    Mol Cells; 2017 Sep; 40(9):613-620. PubMed ID: 28927263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular bases of Alzheimer's disease and other neurodegenerative disorders.
    Maccioni RB; Muñoz JP; Barbeito L
    Arch Med Res; 2001; 32(5):367-81. PubMed ID: 11578751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of tau protein in Alzheimer's disease: The prime pathological player.
    Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
    Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform.
    Kolaj I; Imindu Liyanage S; Weaver DF
    Neurochem Int; 2018 Nov; 120():99-111. PubMed ID: 30098379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease.
    Kazim SF; Iqbal K
    Mol Neurodegener; 2016 Jul; 11(1):50. PubMed ID: 27400746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood Biomarkers in Alzheimer's Disease.
    Mandal PK; Maroon JC; Garg A; Arora NK; Bansal R; Kaushik A; Samkaria A; Kumaran G; Arora Y
    ACS Chem Neurosci; 2023 Nov; 14(22):3975-3978. PubMed ID: 37878665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Small Peptides to Large Proteins against Alzheimer'sDisease.
    Picone P; Sanfilippo T; Vasto S; Baldassano S; Guggino R; Nuzzo D; Bulone D; San Biagio PL; Muscolino E; Monastero R; Dispenza C; Giacomazza D
    Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease and amyloid: culprit or coincidence?
    Skaper SD
    Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice.
    Davtyan H; Hovakimyan A; Kiani Shabestari S; Antonyan T; Coburn MA; Zagorski K; Chailyan G; Petrushina I; Svystun O; Danhash E; Petrovsky N; Cribbs DH; Agadjanyan MG; Blurton-Jones M; Ghochikyan A
    Alzheimers Res Ther; 2019 Dec; 11(1):107. PubMed ID: 31847886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The zinc dyshomeostasis hypothesis of Alzheimer's disease.
    Craddock TJ; Tuszynski JA; Chopra D; Casey N; Goldstein LE; Hameroff SR; Tanzi RE
    PLoS One; 2012; 7(3):e33552. PubMed ID: 22457776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
    Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
    Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct relationships of amyloid-beta and tau deposition to cerebral glucose metabolic networks in Alzheimer's disease.
    Sun X; Nie B; Zhao S; Ai L; Chen Q; Zhang T; Pan T; Wang L; Yin X; Zhang W; Shan B; Liu H; Liang S; Wang G
    Neurosci Lett; 2020 Jan; 717():134699. PubMed ID: 31874218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.